[go: up one dir, main page]

DE68921979D1 - Antikörper für die antilymphozyten-antikörpertherapie. - Google Patents

Antikörper für die antilymphozyten-antikörpertherapie.

Info

Publication number
DE68921979D1
DE68921979D1 DE68921979T DE68921979T DE68921979D1 DE 68921979 D1 DE68921979 D1 DE 68921979D1 DE 68921979 T DE68921979 T DE 68921979T DE 68921979 T DE68921979 T DE 68921979T DE 68921979 D1 DE68921979 D1 DE 68921979D1
Authority
DE
Germany
Prior art keywords
antibodies
antibody therapy
necrosis factor
human alpha
tumour necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921979T
Other languages
English (en)
Other versions
DE68921979T2 (de
Inventor
Wim Buurman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of DE68921979D1 publication Critical patent/DE68921979D1/de
Publication of DE68921979T2 publication Critical patent/DE68921979T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE68921979T 1988-03-11 1989-03-13 Antikörper für die antilymphozyten-antikörpertherapie. Expired - Fee Related DE68921979T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888805792A GB8805792D0 (en) 1988-03-11 1988-03-11 Medicaments
PCT/GB1989/000254 WO1989008460A1 (en) 1988-03-11 1989-03-13 Antibodies for use in antilymphocyte antibody therapy

Publications (2)

Publication Number Publication Date
DE68921979D1 true DE68921979D1 (de) 1995-05-04
DE68921979T2 DE68921979T2 (de) 1995-10-12

Family

ID=10633242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921979T Expired - Fee Related DE68921979T2 (de) 1988-03-11 1989-03-13 Antikörper für die antilymphozyten-antikörpertherapie.

Country Status (6)

Country Link
EP (1) EP0403558B1 (de)
JP (1) JPH03503890A (de)
AT (1) ATE120372T1 (de)
DE (1) DE68921979T2 (de)
GB (1) GB8805792D0 (de)
WO (1) WO1989008460A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1995009652A1 (en) * 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
JP3616091B2 (ja) * 1992-10-08 2005-02-02 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US5733742A (en) * 1993-06-03 1998-03-31 Therapeutic Antibodies Inc. Production of antibody fragments from whole blood
CA2177570A1 (en) * 1993-12-01 1995-06-08 Graham Douglas Fischer Jackson Method of treating intestinal disorders
GB9517538D0 (en) * 1995-08-26 1995-10-25 Therapeutic Antibodies Inc Production and therapeutic combinations, of antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor

Also Published As

Publication number Publication date
EP0403558B1 (de) 1995-03-29
ATE120372T1 (de) 1995-04-15
DE68921979T2 (de) 1995-10-12
JPH03503890A (ja) 1991-08-29
WO1989008460A1 (en) 1989-09-21
EP0403558A1 (de) 1990-12-27
GB8805792D0 (en) 1988-04-13

Similar Documents

Publication Publication Date Title
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
DE69229050D1 (de) Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
DE69309472D1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE68922808D1 (de) Monoklonale Antikörper gegen den Rezeptor des Epidermis-Wachstumsfaktors und diese enthaltende therapeutische Zubereitungen.
ES2147780T3 (es) Compuestos sinteticos afines al extracto de corteza de roble, y procedimiento para utilizar los mismos.
DE69132048D1 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
DE69230798D1 (de) Rekombinante immuntoxine
ES2046173T3 (es) Lineas celulares de hibridoma y sus anticuerpos monoclonales con respecto al factor estimulador de colonias de granulocitos pluripotentes humanos.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
EP0189849A3 (de) Verfahren zur Behandlung von neuroektodermalen Krankheiten und Epithelialkarzinomen bei Menschen
DE69015175D1 (de) Glykoprotein-hormonrezeptor-moleküle.
DE69033810D1 (de) Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
DE69315341D1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
DE3584926D1 (de) Behandlung von oedemen mit hohem proteingehalt durch direktes aufbringen von benzopyronen.
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
GB2233559A (en) Antibodies for use in antilymphocyte antibody therapy

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CELLTECH THERAPEUTICS LTD., SLOUGH, BERKSHIRE, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee